Literature DB >> 3026425

Patterns of reactivity of the monoclonal antibody 791T/36 with different tumour metastases in the liver.

C J Hawkey, C H Holmes, P G Smith, E B Austin, R W Baldwin.   

Abstract

Reactivity of the monoclonal antibody 791T/36 with secondary malignant deposits has been investigated in frozen sections of 74 human liver biopsy specimens. There was no reactivity with hepatocytes but in some instances binding to fibrous tissues and in one case to portal tract lymphocytes was observed. Sections from 9 biopsy specimens contained malignant deposits. In seven of these 791T/36 bound either to malignant cells or to pseudoacinar contents (3 colorectal adenocarcinomas; 1 probable pancreatic adenocarcinoma; 1 medullary cell carcinoma of thyroid; 1 oat cell carcinoma of bronchus and 1 deposit of nodular sclerosing Hodgkins Disease). Two undifferentiated tumours (1 gastric adenocarcinoma and 1 oat cell bronchial carcinoma) showed no antibody binding. The histological pattern of reactivity previously reported with primary tumours appears to be similar in secondary deposits. A wider range of tumours than recognised hitherto binds 791T/36. Whether the binding to fibrous tissue seen in some instances is sufficient to cause diagnostic uncertainty when 791T/36 is used for scanning requires further investigation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3026425      PMCID: PMC2001601          DOI: 10.1038/bjc.1986.255

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Imaging of primary and metastatic colorectal cancer using an 111In-labelled antitumour monoclonal antibody (791T/36).

Authors:  N C Armitage; A C Perkins; M V Pimm; M L Wastie; R W Baldwin; J D Hardcastle
Journal:  Nucl Med Commun       Date:  1985-10       Impact factor: 1.690

2.  Preparation and properties of a drug-carrier-antibody conjugate showing selective antibody-directed cytotoxicity in vitro.

Authors:  M C Garnett; M J Embleton; E Jacobs; R W Baldwin
Journal:  Int J Cancer       Date:  1983-05-15       Impact factor: 7.396

3.  Analysis of a human osteogenic sarcoma antigen and its expression on various human tumour cell lines.

Authors:  D G Campbell; M R Price; R W Baldwin
Journal:  Int J Cancer       Date:  1984-07-15       Impact factor: 7.396

4.  Radioimmunodetection of human colorectal cancers by an anti-tumour monoclonal antibody.

Authors:  P A Farrands; A C Perkins; M V Pimm; M J Embleton; J D Hardy; R W Baldwin; J D Hardcastle
Journal:  Lancet       Date:  1982-08-21       Impact factor: 79.321

5.  Association of antigen expression and DNA ploidy in human colorectal tumors.

Authors:  L G Durrant; R A Robins; N C Armitage; A Brown; R W Baldwin; J D Hardcastle
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

6.  A monoclonal antibody reactive with human hepatocytes.

Authors:  C H Holmes; C J Hawkey; B Gunn; E B Austin; A Fisk; P G Smith; M J Embleton; R W Baldwin; P J Toghill
Journal:  Liver       Date:  1983-10

7.  Localisation of human osteosarcoma by antitumour monoclonal antibody.

Authors:  P A Farrands; A Perkins; L Sully; J S Hopkins; M V Pimm; R W Baldwin; J D Hardcastle
Journal:  J Bone Joint Surg Br       Date:  1983-11

8.  Identification of an anti-human osteogenic sarcoma monoclonal-antibody-defined antigen on mitogen-stimulated peripheral blood mononuclear cells.

Authors:  M R Price; D G Campbell; R W Baldwin
Journal:  Scand J Immunol       Date:  1983-11       Impact factor: 3.487

9.  Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate.

Authors:  M J Embleton; G F Rowland; R G Simmonds; E Jacobs; C H Marsden; R W Baldwin
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

10.  Antigenicity of newly established colorectal carcinoma cell lines.

Authors:  L G Durrant; R A Robins; M V Pimm; A C Perkins; N C Armitage; J D Hardcastle; R W Baldwin
Journal:  Br J Cancer       Date:  1986-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.